research communications
accessof the folded domains of Xrs2 from Saccharomyces cerevisiae
aDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA
*Correspondence e-mail: [email protected]
The MRE11–RAD50–NBS1/Xrs2 (MRN/X) protein complex acts as a first responder in DNA double-strand break repair and telomere-length maintenance, yet the structural architecture of the yeast ortholog Xrs2 has remained unresolved. In this study, we present the first structure of the folded N-terminal region of Xrs2 from Saccharomyces cerevisiae, resolved at 2.38 Å using X-ray crystallography. Like the previously determined crystal structures of Schizosaccharomyces pombe Nbs1, the folded structure of S. cerevisiae Xrs2 adopts an extended three-domain organization at its N-terminus. Electrostatic analysis reveals two distinct charged patches: a positively charged patch on the FHA domain and a negatively charged patch in the cleft between the FHA and BRCT1 domains. This charge segregation is likely to play a role in mediating interactions with various ligands.
Keywords: Nbs1/Xrs2; DNA double-strand breaks; DNA damage repair.
PDB reference: folded domains of Xrs2 from S. cerevisiae, 9ee7
1. Introduction
The MRN/X complex is a multi-protein assembly composed of MRE11, RAD50 and NBS1 in higher eukaryotes or Xrs2 in certain yeast species and serves as an initial sensor and responder to DNA double-strand breaks (DSBs), which are among the most severe forms of DNA damage (Bunting & Nussenzweig, 2013
; Romero-Laorden & Castro, 2017
; Lengauer et al., 1998
; Wang et al., 2004
). In addition to its critical role in detecting, processing and signaling DNA DSBs to initiate the repair process, the MRN/X complex also has an indispensable function in preserving telomere integrity, thereby maintaining genomic stability and preventing premature cellular aging or genome instability (Lamarche et al., 2010
). Mutation of the essential MRN is implicated in the development of prostate, ovarian and breast cancer and can be an underlying cause of diseases such as Nijmegen breakage syndrome (Chrzanowska et al., 2012
; Seemanová et al., 2006
; Carney et al., 1998
) and ataxia–telangiectasia-like disorders (Rahman et al., 2020
; Heikkinen, 2005
).
The universally conserved MRE11 and RAD50 subunits possess Mn2+-dependent nuclease and ATP-hydrolysis activities, respectively (Han & Huang, 2020
; Lieber, 2010
). NBS1/Xrs2 is a scaffolding hub for protein and DNA interactions with the complex (Kim et al., 2017
; Wu et al., 2000
; Oh et al., 2016
; Lu et al., 2012
; Schiller et al., 2012
; Trujillo et al., 2003
). NBS1/Xrs2 contains a folded region at the N-terminus and a long intrinsically disordered region (IDR) at the C-terminus (Fig. 1
a). This folded region contains a forkhead-associated (FHA) domain (Durocher et al., 1999
) followed by tandem BRCA1 C-terminal (BRCT) domains (BRCT1 and BRCT2; Becker et al., 2006
). Phosphothreonine- and phosphoserine-binding sites in the FHA and BRCT1/2 domains, which are responsible for binding to phosphorylated histone γH2AX (Kobayashi et al., 2002
), CtIP/Sae2 (Williams et al., 2009
) and MDC1 (Kim et al., 2006
), alongside interaction motifs for RAD18, MRE11, RNF20, ATM/Tel1, phosphorylation and ubiquitylation sites and a nuclear localization signal (NLS) within the IDR, provide numerous protein-interaction sites on NBS1/Xrs2 (Williams et al., 2009
; Wu et al., 2000
; Oh et al., 2016
; Lu et al., 2012
; Schiller et al., 2012
; Kim et al., 2017
; Lloyd et al., 2009
; Kim et al., 2006
; Wu et al., 2012
; Kobayashi et al., 2002
). These protein–protein interactions are essential for localizing the MRN/X complex to the nuclease and bringing downstream effector proteins to the site of DNA DSBs. It has been proposed that the folded region of NBS1/Xrs2 can engage with other proteins through four potential binding modes: a binding partner can bind exclusively to either the FHA or BRCT1/2 domains, two different partners can bind separately to the FHA and BRCT1/2 domains, or a single partner can bind to both domains simultaneously (Williams et al., 2009
). For example, Tainer and coworkers have shown that Schizosaccharomyces pombe (Sp) Nbs1 binds a phosphothreonine peptide derived from Ctp1 (a homolog of Sae2 in yeast and CtIP in humans) through the FHA domain (Williams et al., 2009
). Additionally, two groups have demonstrated that Saccharomyces cerevisiae (Sc) Xrs2 binds directly to DNA, although it is unknown where this interaction occurs (Trujillo et al., 2003
; Möller et al., 2024
). These observations highlight the crucial role of NBS1/Xrs2 as a scaffolding hub for protein–protein and protein–DNA interactions.
| Figure 1 Structure of the Sc Xrs2325 FHA–BRCT1–BRCT2 region. (a) Cartoon representation of the Sc Xrs2 domain architecture. (b) The crystal of Xrs2325. (c) Ribbon representation of the Sc Xrs2325 with major secondary elements (α-helices and β-strands) labeled. The FHA, BRCT1 and BRCT2 domains are colored red, yellow and blue, respectively, as in (a). All structural representations were made with PyMOL. |
Two X-ray crystal structures of Sp Nbs1 have been determined. Despite being orthologs, Sp Nbs1 and Sc Xrs2 display very low sequence similarity (∼30%), raising intriguing questions about how structural and functional conservation is maintained across such divergent sequences. Additionally, Xrs2, a core component of the yeast MRX complex, mirrors the role of human NBS1 in the MRN complex (both proteins bind and localize CtIP/Sae2 and ATM/Tel1 to sites of DNA DSBs and both bind to DNA). Understanding the architecture of Xrs2 could therefore offer critical insights into how NBS1 operates in humans. Here, we report the first high-resolution (2.38 Å) structure of the folded domains (FHA–BRCT1/2) of Xrs2 from S. cerevisiae, which will advance our understanding of its functions in the DNA damage response and telomere-length maintenance.
2. Materials and methods
2.1. Protein production and purification
2.1.1. Cloning
The folded N-terminal region of Sc Xrs2 (Xrs2325; residues 1–325; UniProt P33301), based on the X-ray crystal structures of Sp Nbs1 (Williams et al., 2009
; Lloyd et al., 2009
), was subcloned from a yeast shuttle vector, generously provided by the Durocher Laboratory (Lunenfeld–Tanenbaum Research Institute, Toronto, Ontario, Canada), into the NdeI and NotI restriction sites of the pET-29 expression vector (Novagen). The reverse PCR primer included the sequence for a TEV protease-cleavable C-terminally 6×His-tagged protein, facilitating downstream purification.
The ligated plasmid was transformed into DH5α chemically competent Escherichia coli cells (Thermo Fisher Scientific) and plated on Luria–Bertani medium containing 50 µg ml−1 kanamycin (LB/Kan). Plasmid DNA was purified from single colonies using a Macherey–Nagel NucleoSpin Plasmid kit. The sequence was confirmed through Sanger sequencing (Genewiz). Details of the cloning procedure and protein expression are provided in Table 1
.
| ||||||||||||||||||||
2.1.2. Protein expression and purification
The Xrs2325 expression plasmid was transformed into BL21 Star (DE3) chemically competent E. coli cells (Thermo Fisher Scientific) and plated on LB/Kan. The resulting colonies were cultured at 37°C in 750 ml LB/Kan. Protein expression was induced by adding 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the culture reached an OD600 of between 0.8 and 1.0; Xrs2325 was expressed at 37°C for 4 h. Following expression, the cells were harvested by centrifugation at 4000g for 30 min, resuspended in lysis buffer (25 mM HEPES, 300 mM NaCl, 25 mM imidazole, 0.1% β-mercaptoethanol pH 7.0) and stored overnight at −20°C. The cells were thawed in an ice bath and incubated with 1 mM phenylmethylsulfonyl fluoride (PMSF) and 0.5 mg ml−1 lysozyme for 20 min with rocking on ice. Cell lysis was performed by homogenization (Avestin) and the lysate was cleared by centrifugation in a JA 25.50 rotor (Beckman Coulter) at 23 000 rev min−1 for 50 min at 4°C. The supernatant was filtered through a 0.45 µm syringe filter (Sartorius) and was loaded onto a 5 ml HisTrap HP column (Cytiva). The bound protein was washed with additional lysis buffer, then with lysis buffer plus 1.2 M NaCl, and was finally eluted with buffer B (25 mM HEPES, 300 mM NaCl, 300 mM imidazole, 0.1% β-mercaptoethanol pH 7.0). TEV protease (1:10 ODU ratio of TEV protease to the eluted protein) was added to cleave off the C-terminal 6×His-tag, and the sample was dialyzed overnight in 1 l fresh lysis buffer at 4°C. After dialysis, the sample was reloaded onto the 5 ml HisTrap HP column and the flowthrough was collected. The purified, cleaved Xrs2325 was concentrated using a 10 kDa molecular-weight cutoff centrifugal concentrator (Millipore), and further purification was performed using a HiLoad 16/600 Superdex 200 pg size-exclusion column (Cytiva) equilibrated with 25 mM HEPES, 300 mM NaCl, 0.1% β-mercaptoethanol pH 7. Fractions containing the ∼37 kDa Xrs2325 were pooled, buffer-exchanged into 100 mM NaCl, 25 mM HEPES, 1%(v/v) β-mercaptoethanol, 2 mM MgSO4 pH 7.0 and concentrated using a 10 kDa molecular-weight cutoff centrifugal concentrator.
2.2. Crystallization
Crystallization experiments were conducted using a protein solution containing Xrs2325 and a DNA hairpin in a 1:1 molar ratio to investigate the proposed interaction between the two macromolecules. The DNA (5′-CACGCACGTAGAAGCTTTTGCTTCTACGTGCGTGAC-3′) was ordered from Integrated DNA Technologies (IDT) and was buffer-exchanged into the protein–DNA buffer solution (Table 2
). Hanging-drop crystallization was performed by mixing 2 µl of the protein–DNA solution with 2 µl well solution and allowing equilibration at room temperature for one week. Multiple crystallization plates were used to explore different conditions, and an optimal well condition of 3.0 M NaCl, 0.1 M Tris pH 8.3 was identified. Crystallization details are provided in Table 2
.
| ||||||||||||||||||||
2.3. Data collection and processing
Data were acquired on NSLS-II beamline 17-ID-2 with a Dectris EIGER 16M detector under 100 K cryo-conditions at a wavelength of 0.979 Å. Data were processed using XDS (Kabsch, 2010
). Anisotropic diffraction analysis and truncation were performed with STARANISO (https://staraniso.globalphasing.org/). The X-ray diffraction data collection is summarized in Table 3
.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
2.4. Structure solution and structure refinement
using the of Sp Nbs1 (PDB entry 3hue; Williams et al., 2009
) did not provide adequate phasing information; therefore, molecular-replacement search models were generated via AlphaFold2 (Jumper et al., 2021
; Tunyasuvunakool et al., 2021
). Multiple AlphaFold2 models were generated and subsequently filtered based on their agreement with methyl-based solution-state NMR data (Vigneswaran et al., 2025
). The protein side chains of the best-fitting AlphaFold2 model were truncated using CHAINSAW (Stein, 2008
) in CCP4 (Agirre et al., 2023
) and initial phases were obtained from Phaser-MR. Refinement was performed using phenix.refine (Liebschner et al., 2019
) and Coot (Emsley & Cowtan, 2004
). After 67 cycles of refinement, PDB-REDO (Van Beusekom et al., 2018
; Joosten et al., 2014
) was implemented in an effort to improve the Rwork and Rfree values. Further of the structure was carried out using Phenix and Coot for 46 further cycles to reduce the clashscore and the number of rotamer outliers, which led to the final resolved model with Rwork and Rfree values of 0.2982 and 0.3119, respectively. Details of the structure-refinement statistics are provided in Table 4
. Note that no density was observed for the DNA molecule, and the final model is Xrs2325 alone. The final model has been deposited in the Research Collaboratory for Structural Bioinformatics Protein Data Bank as PDB entry 9ee7.
| ||||||||||||||||||||||||||||||||||
3. Results and discussion
Previous research has shown that full-length Sc Xrs2 binds to DNA (Trujillo et al., 2003
; Möller et al., 2024
). To structurally characterize this interaction, we attempted to co-crystallize the folded N-terminal region of Sc Xrs2 (residues 1–325) with DNA. A 9-, 11-, 13- or 15-base-pair hairpin DNA containing a four-nucleotide loop and a two-nucleotide 3′-overhang was added to Sc Xrs2325 at equimolar concentrations. Although the highest quality diffracting crystal was obtained for the 15-base-pair DNA hairpin and Xrs2325 complex, the final electron density showed no evidence of bound DNA. This result suggests that if the DNA does interact with the N-terminal region of Sc Xrs2, the interaction is too transient or unstable under the specific conditions used for crystal formation to be observed. Nevertheless, Sc Xrs2325 was successfully crystallized by the hanging-drop vapor-diffusion method at 25°C (Fig. 1
b). The crystal belonged to space group P6122, containing one Xrs2325 monomer in the The structure was determined at a resolution of 2.38 Å (Fig. 1
c). Structural refinement yielded Rwork and Rfree values of 0.2982 and 0.3119, respectively. The loop residues Asn7–Gly13, Asn58–Leu63, Ser95–Val97 and Gly316–Lys325 were excluded from the structural model due to weak electron density in these regions.
Modeling the structure of Xrs2325 into the electron density was a difficult process. After 67 rounds of with little significant improvement in the Rwork and Rfree values, PDB-REDO was utilized. PDB-REDO calculated a model with Rwork and Rfree values that were reduced from 0.2834 and 0.3073 to 0.2417 and 0.3015, respectively. However, the clashscore and the number of rotamer outliers increased. 46 additional rounds of were used to reduce the clashscore and rotamer outliers, although this resulted in increased Rwork and Rfree values. Analysis of the geometric quality of the final model revealed strained backbone conformations in several loop regions: the Ramachandran statistics showed 1.03% and 11.30% of the residues in outlier and allowed space, respectively. Many of these residues map to disordered or flexible segments in the FHA and BRCT2 domains coinciding with omitted or poorly resolved loop regions. The difficulty in model building is further reflected in the elevated r.m.s.d. value for bond angles (1.12°).
To understand the reason for the difficulty in model building, we analyzed the calculated B factors (Fig. 2
). The global average B factor for all atoms (excluding crystallographic waters) in Xrs2325 was 83.70 Å2, with the smallest B factor in Lys178 of the BRCT1 domain (50.06 Å2) and the largest in His65 of the FHA domain (130.38 Å2). Visualization of the Cα B factors on the structure (Fig. 2
a) or the plot of the residue average B factor plotted against the sequence (Fig. 2
b) reveals two phenomena. Firstly, BRCT1 has the smallest B factors (all-atom average of 72.85 Å2 for residues 118–157 and 175–224), whereas BRCT2 has the largest B factors (all-atom average of 92.84 Å2 for residues 158–174 and 225–315). The all-atom average B factor for the FHA domain is 81.08 Å2 (residues 1–117). This high level of disorder contrasts starkly with the previously published models of Sp Nbs1 (PDB entries 3hue and 3i0m), which have average B factors of 33.32 and 33.12 Å2, respectively. Secondly, within each domain many of the loop regions contain relatively high B factors. This trend is especially obvious for residues preceding/proceeding (for example, Asn7–Gly13) or adjacent to (Lys41–Asn42) omitted or poorly resolved loops, as expected (Djinovic-Carugo & Carugo, 2015
). Additionally, the high solvent content (73.73%) of our crystal further increased the overall crystal mobility and disorder, contributing to the elevated B factors across the structure (Carugo, 2018
). Together, the high level of disorder and highly flexible loop regions, particularly in the FHA domain, led to weak or missing electron density and made accurate modeling of side chains difficult without introducing steric clashes. In summary, the dynamic and/or disordered nature and structural strain within the FHA and BRCT2 loop regions posed a significant limitation for full atomic-level resolution.
| Figure 2 Analysis of Xrs2325 crystallographic B factors. (a) Putty representation of Xrs2325 illustrating crystallographic B factors. The tube thickness and blue–green–red color gradient depict backbone Cα B factors. (b) Scatter plot of the average residue B factor versus residue number. Data points are colored by domain: FHA in red circles, BRCT1 in yellow squares and BRCT2 in blue triangles. The horizontal line depicts the global average B factor of 83.07 Å2. |
As seen in the previously published crystal structures of the homologous folded N-terminal region of Sp Nbs1 (Williams et al., 2009
; Lloyd et al., 2009
), the model of Sc Xrs2325 revealed an extended structure with approximate dimensions of 82 × 31 × 24 Å and three distinct domains organized sequentially from the N-terminus: FHA, BRCT1 and BRCT2 domains (Fig. 1
c). The FHA domain is comprised of eight antiparallel β-strands, whereas the BRCT1 domain contains three α-helices and three short β-strands. The BRCT2 domain, in contrast, has six α-helices and five β-strands (Fig. 1
c). A comparison of the Sc Xrs2325 with the Sp Nbs1 structures revealed notable differences. Alignment with the reported by Tainer and coworkers for Sp Nbs1 (PDB entry 3hue) resulted in a backbone-atom root-mean-squared deviation (r.m.s.d.) of 6.68 Å (n = 996 atoms), whereas the structure reported by Smerdon and coworkers for Sp Nbs1 (PDB entry 3i0m) had an r.m.s.d. of 6.32 Å (n = 1028 atoms) to the Sc Xrs2325 model (Fig. 3
a). Generally, the overall structure of the FHA and BRCT1 domains in the three crystal structures is similar; however, several loops in the FHA domain showed potential differences between Xrs2 and Nbs1. Specifically, the unstructured loop between β6 and β7 in Sc Xrs2325 adopts a two-stranded β-sheet conformation in Sp Nbs1 (highlighted in magenta in Fig. 3
b). Furthermore, the loop between β5 and β6 in Sc Xrs2 is unresolved, whereas the resolved loop in Sp Nbs1 contains an additional helix (highlighted in orange in Fig. 3
b). In contrast, comparison of the BRCT2 domains revealed significant differences between Sc Xrs2 and Sp Nbs1 (Fig. 3
c). Although the overall BRCT2 architecture is conserved, substantial variations were observed in the relative lengths of the α-helices and β-strands, and many of these secondary-structural elements are translated relative to one another. In support of this observation, the alignment of the FHA, BRCT1 and BRCT2 domains of Sc Xrs2325 with Sp Nbs1 (PDB entry 3hue) yielded backbone-atom r.m.s.d. values of 7.13 Å (n = 249 atoms), 8.09 Å (n = 108 atoms) and 10.61 Å (n = 177 atoms), respectively, indicating that the largest deviation occurs in the BRCT2 domain, consistent with the larger B factors observed for this domain. On the other hand, the Sc Xrs2 model in the AlphaFold2 database (version 4) gave a backbone-atom r.m.s.d. of 1.67 Å (n = 1196 atoms) relative to the reported here. When compared with the ColabFold model of Sc Xrs2 that we previously filtered using residual dipolar couplings (Vigneswaran et al., 2025
), the r.m.s.d. was 1.61 Å (n = 1200 atoms). These r.m.s.d.s indicate similar backbone positioning between the computational models of Sc Xrs2, with much of the variation occurring in the side-chain positions.
| Figure 3 Structural comparison of Sc Xrs2325 and Sp Nbs1329. (a) Overlay of the crystal structure of Sc Xrs2325 (colored as in Fig. 1 |
To explore the potential bipartite binding framework, we analyzed the surface-charge distribution of Xrs2325. The Sc Xrs2325 lacks several side chains, which prevented electrostatic surface analysis using Adaptive Poisson–Boltzmann Solver (APBS) electrostatics calculations. To address this, the side-chain heavy atoms which were not modeled were reintroduced to the calculated structure using Phenix and Coot, and the electrostatic surface potential was determined. The surface-charge distribution revealed distinct positively and negatively charged regions, which may play a role in protein–protein or protein–DNA interactions (Fig. 4
). A prominent positively charged surface is localized on the FHA domain and is formed by residues Arg32, Lys35, Lys41, Lys44, Arg48, His50, Lys54, Lys73, Lys75, Lys81, Lys82 and Lys85 (Fig. 4
). A similar positively charged surface was observed in the X-ray crystal structures of Sp Nbs1 and forms the binding site for the phosphothreonine peptide derived from Ctp1 (Williams et al., 2009
). Conservation of this charged region suggests that the homologous phosphorylated Sc Sae2 peptide binds to the same region. Thus, this region serves as a key site for binding partners, accommodating post-translationally modified proteins, such as those containing phosphorylated serine or phosphorylated threonine, or potentially other negatively charged biomolecules such as DNA.
| | Figure 4 Electrostatic surface-charge representation of Sc Xrs2325. (a) The electrostatic surface potential was calculated using APBS and is colored according to calculated charge from red (−5 kT/e) to blue (+5 kT/e). (b) The structure in (a) rotated 90°. |
To explore potential ligand binding in the BRCT repeats of Sc Xrs2, we compared our structure with that of the human TopBP1 tandem BRCT7/8 domains (PDB entry 3al3; Leung et al., 2011
), which has the BACH1 phosphopeptide bound to a positively charged region between its tandem BRCT domains. An overlay of Xrs2325 with the TopBP1 BRCT7/8 domains revealed a similar, moderately positively charged patch in the BRCT1/2 domains of Xrs2325, formed by residues His126, Arg131, Lys159, Arg166, Lys240 and Lys244 (Fig. 5
). This suggests that the BRCT1/2 domain of Xrs2325 could bind negatively charged partners in a similar manner.
| Figure 5 Structural comparison of Sc Xrs2 and the TopBP1 BRCT7/8–BACH1 complex. (a) Structural overlay of the crystal structure of Sc Xrs2325 (colored as in Fig. 1 |
Interestingly, a negatively charged region, located between the FHA and BRCT1 domains and formed by residues Glu113, Glu115, Glu119, Asp201 and Glu202 (Fig. 4
), is positioned 180° opposite to the positively charged patch in BRCT1/2. This negatively charged region is also conserved in the BRCT domains of Sp Nbs1 and TopBP1. Thus, this region could play a role in directing positively charged partners to bind either to the FHA domain or within BRCT1/2. Alternatively, it raises the possibility that this negatively charged region itself could interact with a positively charged partner.
A previous study by Tainer and coworkers proposed an arginine `switch' (Arg16) in the FHA domain of Sp Nbs1, which rotates upon Ctp1 binding to interact with Glu193 and Asp194 in the BRCT1 domain (Fig. 6
a). This switch may trigger an allosteric movement of the BRCT2 domain, resulting in a BRCT2 domain rotation of ∼20°. Intriguingly, the crystal structure of Sc Xrs2325 revealed structurally analogous residues in the FHA domain: Arg5 and Ser19 in the FHA domain are positioned near Asp201 in the BRCT1 domain and may mirror the role of the Sp Nbs1 arginine switch (Fig. 6
b). Multiple sequence alignment across various species (Becker et al., 2006
) demonstrated that these charged residues are conserved at equivalent positions, highlighting the evolutionary preservation of this regulatory mechanism.
| | Figure 6 Structural interface between the FHA and BRCT1 domains of Sp Nbs1 and Sc Xrs2, highlighting structural analogy. (a) Structural overlay of Sp Nbs1 in its Ctp1-bound (PDB entry 3huf, green) and apo (PDB entry 3hue, blue) states (Williams et al., 2009 |
4. Conclusion
This study is the first experimental structural elucidation of the N-terminal folded core of Sc Xrs2 and provides interesting insights into its molecular architecture. Firstly, it confirms the presence of the conserved FHA–BRCT1–BRCT2 domains in this protein. Secondly, analysis of the B factors suggests significant disorder and/or dynamics within the loop regions of the FHA domain and the entire BRCT2 domain. Additionally, comparative analyses with homologous structures demonstrate the presence of a highly conserved positively charged patch within the FHA domain and tandem BRCT1/2 domains, alongside a moderately conserved negatively charged patch situated between the FHA and BRCT1 domains. These conserved electrostatic features play an important role in mediating the protein–protein interactions essential for the repair of damaged DNA.
Acknowledgements
We sincerely thank Dr Daniel Durocher (Lunenfeld–Tanenbaum Research Institute, Toronto, Ontario, Canada) for providing the Xrs2 yeast shuttle plasmid, Marella Canny (UMN) for critically reading the manuscript and the members of the Latham laboratory for their valuable discussions and support. Data collection was performed at the Center for Bio-Molecular Structure (CBMS), which is primarily funded by the NIH–NIGMS through a Center Core P30 Grant (P30GM133893) and the DOE Office of Biological and Environmental Research (KP1607011). NSLS-II is a US DOE Office of Science User Facility operated under Contract No. DE-SC0012704. Data for this publication were collected through beamtime awarded via NE-CAT BAG proposal No. 311950.
Conflict of interest
The authors declare no conflicts of interest.
Funding information
This project was funded in whole or in part with Federal funds from the National Institute of General Medical Sciences, National Institutes of Health under grant No. R35GM128906 (to MPL).
References
Agirre, J., Atanasova, M., Bagdonas, H., Ballard, C. B., Baslé, A., Beilsten-Edmands, J., Borges, R. J., Brown, D. G., Burgos-Mármol, J. J., Berrisford, J. M., Bond, P. S., Caballero, I., Catapano, L., Chojnowski, G., Cook, A. G., Cowtan, K. D., Croll, T. I., Debreczeni, J. É., Devenish, N. E., Dodson, E. J., Drevon, T. R., Emsley, P., Evans, G., Evans, P. R., Fando, M., Foadi, J., Fuentes-Montero, L., Garman, E. F., Gerstel, M., Gildea, R. J., Hatti, K., Hekkelman, M. L., Heuser, P., Hoh, S. W., Hough, M. A., Jenkins, H. T., Jiménez, E., Joosten, R. P., Keegan, R. M., Keep, N., Krissinel, E. B., Kolenko, P., Kovalevskiy, O., Lamzin, V. S., Lawson, D. M., Lebedev, A. A., Leslie, A. G. W., Lohkamp, B., Long, F., Malý, M., McCoy, A. J., McNicholas, S. J., Medina, A., Millán, C., Murray, J. W., Murshudov, G. N., Nicholls, R. A., Noble, M. E. M., Oeffner, R., Pannu, N. S., Parkhurst, J. M., Pearce, N., Pereira, J., Perrakis, A., Powell, H. R., Read, R. J., Rigden, D. J., Rochira, W., Sammito, M., Sánchez Rodríguez, F., Sheldrick, G. M., Shelley, K. L., Simkovic, F., Simpkin, A. J., Skubak, P., Sobolev, E., Steiner, R. A., Stevenson, K., Tews, I., Thomas, J. M. H., Thorn, A., Valls, J. T., Uski, V., Usón, I., Vagin, A., Velankar, S., Vollmar, M., Walden, H., Waterman, D., Wilson, K. S., Winn, M. D., Winter, G., Wojdyr, M. & Yamashita, K. (2023). Acta Cryst. D79, 449–461. Web of Science CrossRef IUCr Journals Google Scholar
Becker, E., Meyer, V., Madaoui, H. & Guerois, R. (2006). Bioinformatics, 22, 1289–1292. Web of Science CrossRef PubMed CAS Google Scholar
Bunting, S. F. & Nussenzweig, A. (2013). Nat. Rev. Cancer, 13, 443–454. Web of Science CrossRef CAS PubMed Google Scholar
Carney, J. P., Maser, R. S., Olivares, H., Davis, E. M., Le Beau, M., Yates, J. R., Hays, L., Morgan, W. F. & Petrini, J. H. J. (1998). Cell, 93, 477–486. Web of Science CrossRef CAS PubMed Google Scholar
Carugo, O. (2018). BMC Bioinformatics, 19, 61. Google Scholar
Chrzanowska, K. H., Gregorek, H., Dembowska-Bagińska, B., Kalina, M. A. & Digweed, M. (2012). Orphanet J. Rare Dis. 7, 13. Web of Science CrossRef PubMed Google Scholar
Djinovic-Carugo, K. & Carugo, O. (2015). Intrinsically Disord. Proteins, 3, e1095697. PubMed Google Scholar
Durocher, D., Henckel, J., Fersht, A. R. & Jackson, S. P. (1999). Mol. Cell, 4, 387–394. Web of Science CrossRef PubMed CAS Google Scholar
Emsley, P. & Cowtan, K. (2004). Acta Cryst. D60, 2126–2132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Han, J. & Huang, J. (2020). Genome Instab. Dis. 1, 10–19. CrossRef Google Scholar
Heikkinen, K. (2005). Carcinogenesis, 27, 1593–1599. Web of Science CrossRef Google Scholar
Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. (2014). IUCrJ, 1, 213–220. Web of Science CrossRef CAS PubMed IUCr Journals Google Scholar
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., Back, T., Petersen, S., Reiman, D., Clancy, E., Zielinski, M., Steinegger, M., Pacholska, M., Berghammer, T., Bodenstein, S., Silver, D., Vinyals, O., Senior, A. W., Kavukcuoglu, K., Kohli, P. & Hassabis, D. (2021). Nature, 596, 583–589. Web of Science CrossRef CAS PubMed Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Kim, J.-E., Minter-Dykhouse, K. & Chen, J. (2006). Mol. Carcinog. 45, 403–408. Web of Science CrossRef PubMed CAS Google Scholar
Kim, J. H., Grosbart, M., Anand, R., Wyman, C., Cejka, P. & Petrini, J. H. J. (2017). Cell. Rep. 18, 496–507. Web of Science CrossRef CAS PubMed Google Scholar
Kobayashi, J., Tauchi, H., Sakamoto, S., Nakamura, A., Morishima, K., Matsuura, S., Kobayashi, T., Tamai, K., Tanimoto, K. & Komatsu, K. (2002). Curr. Biol. 12, 1846–1851. Web of Science CrossRef PubMed CAS Google Scholar
Lamarche, B. J., Orazio, N. I. & Weitzman, M. D. (2010). FEBS Lett. 584, 3682–3695. Web of Science CrossRef CAS PubMed Google Scholar
Lengauer, C., Kinzler, K. W. & Vogelstein, B. (1998). Nature, 396, 643–649. Web of Science CrossRef CAS PubMed Google Scholar
Leung, C. C. Y., Gong, Z., Chen, J. & Glover, J. N. M. (2011). J. Biol. Chem. 286, 4292–4301. Web of Science CrossRef CAS PubMed Google Scholar
Lieber, M. R. (2010). Annu. Rev. Biochem. 79, 181–211. Web of Science CrossRef CAS PubMed Google Scholar
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., Moriarty, N. W., Oeffner, R. D., Poon, B. K., Prisant, M. G., Read, R. J., Richardson, J. S., Richardson, D. C., Sammito, M. D., Sobolev, O. V., Stockwell, D. H., Terwilliger, T. C., Urzhumtsev, A. G., Videau, L. L., Williams, C. J. & Adams, P. D. (2019). Acta Cryst. D75, 861–877. Web of Science CrossRef IUCr Journals Google Scholar
Lloyd, J., Chapman, J. R., Clapperton, J. A., Haire, L. F., Hartsuiker, E., Li, J., Carr, A. M., Jackson, S. P. & Smerdon, S. J. (2009). Cell, 139, 100–111. Web of Science CrossRef PubMed CAS Google Scholar
Lu, C.-S., Truong, L. N., Aslanian, A., Shi, L. Z., Li, Y., Hwang, P. Y.-H., Koh, K. H., Hunter, T., Yates, J. R., Berns, M. W. & Wu, X. (2012). J. Biol. Chem. 287, 43984–43994. Web of Science CrossRef CAS PubMed Google Scholar
Möller, C., Sharma, R., Öz, R., Reginato, G., Cannavo, E., Ceppi, I., Sriram, K. K., Cejka, P. & Westerlund, F. (2024). Biochem. Biophys. Res. Commun. 695, 149464. Web of Science PubMed Google Scholar
Oh, J., Al-Zain, A., Cannavo, E., Cejka, P. & Symington, L. S. (2016). Mol. Cell, 64, 405–415. Web of Science CrossRef CAS PubMed Google Scholar
Rahman, S., Canny, M. D., Buschmann, T. A. & Latham, M. P. (2020). Cells, 9, 1678. Web of Science CrossRef PubMed Google Scholar
Romero-Laorden, N. & Castro, E. (2017). Curr. Probl. Cancer, 41, 251–264. Web of Science PubMed Google Scholar
Schiller, C. B., Lammens, K., Guerini, I., Coordes, B., Feldmann, H., Schlauderer, F., Möckel, C., Schele, A., Strässer, K., Jackson, S. P. & Hopfner, K.-P. (2012). Nat. Struct. Mol. Biol. 19, 693–700. Web of Science CrossRef CAS PubMed Google Scholar
Seemanová, E., Sperling, K., Neitzel, H., Varon, R., Hadac, J., Butova, O., Schröck, E., Seeman, P. & Digweed, M. (2006). J. Med. Genet. 43, 218–224. Web of Science PubMed Google Scholar
Stein, N. (2008). J. Appl. Cryst. 41, 641–643. Web of Science CrossRef CAS IUCr Journals Google Scholar
Trujillo, K. M., Roh, D. H., Chen, L., Van Komen, S., Tomkinson, A. & Sung, P. (2003). J. Biol. Chem. 278, 48957–48964. Web of Science CrossRef PubMed CAS Google Scholar
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., Velankar, S., Kleywegt, G. J., Bateman, A., Evans, R., Pritzel, A., Figurnov, M., Ronneberger, O., Bates, R., Kohl, S. A. A., Potapenko, A., Ballard, A. J., Romera-Paredes, B., Nikolov, S., Jain, R., Clancy, E., Reiman, D., Petersen, S., Senior, A. W., Kavukcuoglu, K., Birney, E., Kohli, P., Jumper, J. & Hassabis, D. (2021). Nature, 596, 590–596. Web of Science CrossRef CAS PubMed Google Scholar
van Beusekom, B., Touw, W. G., Tatineni, M., Somani, S., Rajagopal, G., Luo, J., Gilliland, G. L., Perrakis, A. & Joosten, R. P. (2018). Protein Sci. 27, 798–808. Web of Science CrossRef CAS PubMed Google Scholar
Vigneswaran, A., Buschmann, T. A. & Latham, M. P. (2025). J. Magn. Reson. 374, 107865. Web of Science CrossRef PubMed Google Scholar
Wang, Z., Cummins, J. M., Shen, D., Cahill, D. P., Jallepalli, P. V., Wang, T.-L., Parsons, D. W., Traverso, G., Awad, M., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., Markowitz, S. D., Goldberg, M. L., Karess, R., Kinzler, K. W., Vogelstein, B., Velculescu, V. E. & Lengauer, C. (2004). Cancer Res. 64, 2998–3001. Web of Science CrossRef PubMed CAS Google Scholar
Williams, R. S., Dodson, G. E., Limbo, O., Yamada, Y., Williams, J. S., Guenther, G., Classen, S., Glover, J. N. M., Iwasaki, H., Russell, P. & Tainer, J. A. (2009). Cell, 139, 87–99. Web of Science CrossRef PubMed CAS Google Scholar
Wu, H.-H., Wu, P.-Y., Huang, K.-F., Kao, Y.-Y. & Tsai, M.-D. (2012). Biochemistry, 51, 575–577. Web of Science CrossRef CAS PubMed Google Scholar
Wu, X., Ranganathan, V., Weisman, D. S., Heine, W. F., Ciccone, D. N., O'Neill, T. B., Crick, K. E., Pierce, K. A., Lane, W. S., Rathbun, G., Livingston, D. M. & Weaver, D. T. (2000). Nature, 405, 477–482. Web of Science CrossRef PubMed CAS Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
access
journal menu



